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Abstract
Background: Lymphatic filariasis (LF), also known as elephantiasis, is a neglected tropical disease (NTD) targeted for
elimination through a Global Programme to Eliminate LF (GPELF). Between 2000 and 2014, the GPELF has delivered
5.6 billion treatments to over 763 million people. Updating the estimated health and economic benefits of this
significant achievement is important in justifying the resources and investment needed for eliminating LF.
Method: We combined previously established models to estimate the number of clinical manifestations and
disability-adjusted life years (DALYs) averted from three benefit cohorts (those protected from acquiring infection,
those with subclinical morbidity prevented from progressing and those with clinical disease alleviated). The economic
savings associated with this disease prevention was then analysed in the context of prevented medical expenses
incurred by LF clinical patients, potential income loss through lost-labour, and prevented costs to the health
system to care for affected individuals. The indirect cost estimates were calculated using the human capital
approach. A combination of four wage sources was used to estimate the fair market value of time for an
agricultural worker with LF infection (to ensure a conservative estimate, the lowest wage value was used).
Results: We projected that due to the first 15 years of the GPELF 36 million clinical cases and 175 (116–250)
million DALYs will potentially be averted. It was estimated that due to this notable health impact, US$100.5
billion will potentially be saved over the lifetimes of the benefit cohorts. This total amount results from summing
the medical expenses incurred by LF patients (US$3 billion), potential income loss (US$94 billion), and costs to
the health system (US$3.5 billion) that were projected to be prevented. The results were subjected to sensitivity
analysis and were most sensitive to the assumed percentage of work hours lost for those suffering from chronic
disease (changing the total economic benefit between US$69.30–150.7 billion).
Conclusions: Despite the limitations of any such analysis, this study identifies substantial health and economic
benefits that have resulted from the first 15 years of the GPELF, and it highlights the value and importance of
continued investment in the GPELF.
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Background
Lymphatic filariasis (LF), also known as elephantiasis, is
a neglected tropical disease (NTD) now targeted for
elimination through the Global Programme to Eliminate
LF (GPELF). When this Programme began in 2000, there
were 1.3 billion people in 73 endemic countries at-risk
of LF. It was estimated that approximately 120 million
people were infected with LF, of which 40 million were
suffering from overt clinical disease – manifested as pain-
ful severe swelling due to lymphedema (an accumulation
of lymphatic fluid generally in the limbs) and hydrocele
(fluid accumulation in the scrotal sac) [1, 2].
As a public health problem, LF is treated with preventa-
tive chemotherapy (Table 1) using a combination of either
albendazole and ivermectin (in areas co-endemic with on-
chocerciasis) or albendazole and diethylcarbamazine (DEC)
elsewhere. To achieve its elimination goals, the GPELF
guides endemic countries in implementing annual, single-
dose mass drug administration (MDA) against LF using ei-
ther of these two drug regimens. The MDA strategy is
unique in targeting all people of all ages in the endemic
population who are eligible to take these safe and effective
medicines (Table 1). This strategy has been shown to be
feasible, inexpensive and cost-effective [2, 3], principally
because the drugs used are donated by pharmaceutical
partners.
Over the first eight operational years of the GPELF
(2000–2007), more than 1.9 billion MDA treatments
were administered to approximately 570 million individ-
uals in 48 countries. This notable programmatic achieve-
ment resulted in a significant impact on the health of
endemic populations [2]. A previous analysis by Chu et al.
[4] estimated that due to GPELF activities between 2000
and 2007, over US$23 billion of economic benefits would
be accrued by individuals and the health systems in MDA-
treated areas (over the lifetime of those treated).
Since 2007, more countries have started MDA and others
have expanded their treatment coverage (Fig. 1). This was
made possible largely by new resource commitments
for programme implementation from bilateral donors
(especially DFID and USAID), the Bill & Melinda Gates
Foundation, and other non-governmental development
organizations (NGDOs) – funds that were needed to
deliver the increased drug contributions from industry
partners (initially GSK and Merck & Co, and more re-
cently Eisai).
Assessment of the economic and health impact of the
GPELF was first made after 8 years of programme activity
[2, 4], but now given both the expansion of the programme
during its subsequent seven years and the new strategies
available for modelling its impact, the present manuscript
aims to provide updated estimates of the health and eco-
nomic benefits of the GPELF from 2000 to 2014.
Methods
GPELF – numbers at risk, and numbers treated
As seen in Table 2, since 2007, the programme has ex-
panded to a further 13 countries and delivered over 3.68
billion more treatments (Table 2). Therefore, the num-
ber of people at-risk of infection and the numbers
treated that were reported by Chu et al. [4] could be up-
dated from the World Health Organisation (WHO) PCT
databank [5] and the 2014 GPELF progress report [6].
The numbers of people at-risk of infection were esti-
mated from data resulting from new mapping activities,
and the numbers and populations treated, from coun-
tries’ annual reports to WHO and the drug donation
programmes (summarized in the PCT databank [5]).
Epidemiological model and assumptions
Based on previous analyses [2, 4], the following key as-
sumptions were made (Fig. 2 and Table 3):
 Before control, 10 % of the at-risk population would
be infected with LF, and this ratio remains constant
in the absence of MDA [2].
Table 1 Glossary
Acute disease/acute adenolymphangitis (ADL): defined by
symptoms of pain, tenderness, local swelling, and warmth in the groin
or limbs with constitutional symptoms (such as fever, nausea, and
vomiting).
Benefit Cohort 1: individuals protected from acquiring infection.
Benefit Cohort 2: individuals with existing subclinical morbidity
protected from progression to clinical disease.
Benefit Cohort 3: individuals with existing clinical morbidity for whom
clinical morbidity was alleviated.
Chronic disease: disease that is persistent (here limited specifically to
hydrocele and lymphedema)
Clinical disease: a disease that has recognizable clinical signs and
symptoms (i.e. any acute or chronic cases).
Direct costs: costs associated with medical resource utilization, which
include the cost borne by the patients (for the medication and transport
etc.) and the health system (i.e. personnel and capital resources etc.).
Discounting/Discount rate: the process for adjusting future costs and
outcomes to a “present value” to reflect the fact that a dollar is worth
more today than it would be worth tomorrow. The discount rate
determines the strength for the time preference.
Human capital approach: human-capital method takes the patient’s
perspective and counts any hour not worked as an hour lost. By
contrast, the friction-cost method takes the employer’s perspective, and
only counts as lost those hours not worked until another employee
takes over the patient’s work [86].
Hydrocele: fluid accumulation in the scrotal sac.
Indirect costs: expenses incurred from the cessation or reduction of
work productivity as a result of the morbidity and mortality associated
with a given disease.
Lymphedema: an accumulation of lymphatic fluid generally in the limbs
Mass drug administration (MDA)/preventative chemotherapy:
administration of drugs to whole target population.
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 One-third of those with LF infections would have
clinical disease (3.33 % of the total at-risk
population).
 The other two-thirds of individuals infected with LF
actually have subclinical morbidity [1]; half of these
cases would progress to overt clinical disease in their
lifetimes [2].
 Cases of clinical disease occur in the following
proportion: 62.5 % hydrocele, 37.5 % lymphedema
[7]. It was assumed that the relative frequency of the
clinical disease presentations remains stable among
those infected individuals.
For LF, acute disease refers to recurring attacks of
acute adenolymphangitis (ADL), defined by symptoms of
pain, tenderness, local swelling, and warmth in the groin
or limbs with constitutional symptoms (such as fever,
nausea, and vomiting) [8–10]. It was assumed that these
episodes last on average 4 days [8, 10–17]. Seventy per-
cent of hydrocele and 95 % lymphedema patients were
assumed to experience ADL episodes, with an average of
two and four episodes per year respectively [8, 10–17].
These assumptions were varied in the sensitivity analysis.
Calculating the health impact of the GPELF
Benefit Cohort Populations and the impact of treatment
For this analysis, the only individuals assumed to be in-
curring a health (and later, economic) burden due to LF
were those with clinical disease. Consequently, three broad
groups of individuals were recognized to have benefits
Fig. 1 The number of countries that have started a LF MDA programme (a) and the cumulative number of treatments (b) provided by the GPELF
over time. Data from the PCT databank [5]. Values in black indicate data provided after the timeframe of the previous analyses (2000–2007) [2, 4].
Insert in panel b illustrates the proportion of the cumulative number of treatments (2000–2014) in each of the different WHO regions (AMRO
Region of the Americas, AFRO African Region, EMRO Eastern Mediterranean Region, WPRO Western Pacific Region, SEARO South-East Asia Region)
Table 2 GPELF MDA treatments (2000–2014)




AMRO Brazil, Dominican Republic, Guyana, Haiti. 14 10
AFRO Benin, Burkina Faso, Cameroon, Central African Republic, Comoros, Congo,
Côte d’Ivoire, Democratic Republic of Congo, Ethiopia, Ghana, Guinea,
Guinea-Bissau, Kenya, Liberia, Madagascar, Malawi, Mali, Mozambique,
Niger, Nigeria, Senegal, Sierra Leone, Tanzania (incl. Zanzibar),
Togo, Uganda.
425 191
EMRO Egypt, Sudan Yemen. 23 3
WPRO American Samoa, Brunei Darussalam, Cambodia, Cook Islands, Fed. States of
Micronesia, Fiji, French Polynesia, Kiribati, Lao PDR, Marshall Islands, Malaysia,
Niue, Papua New Guinea, Philippines, Samoa, Tonga, Tuvalu, Vanuatu, Vietnam,
Wallis and Futuna.
45 24
SEARO Bangladesh, India, Indonesia, Maldives, Myanmar, Nepal, Sri Lanka, Thailand,
Timor-Leste.
902 536
All Regions 61 countries in totald 1409 763
AMRO Region of the Americas, AFRO African Region, EMRO Eastern Mediterranean Region, WPRO Western Pacific Region, SEARO South-East Asia Region
aCountries that started since 2007 are indicated in bold
bData taken from [5, 6]
cA conservative approach was taken and the number of uniquely treated individuals in any one country was assumed to be the maximum number of individuals
treated in any single MDA for each country
d Palau has passed the TAS survey but never started MDA so is not included
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from the MDA treatment provided under the GPELF
(Fig. 3):
Benefit Cohort 1: individuals protected from acquiring
infection
Since the beginning of the programme in 2000 through
the end of 2014, over 5.6 billion doses of anthelmintics
have been administered to populations in 61 of the en-
demic countries (Table 4 and Fig. 1). This mass treatment
will have had a major impact on the rate of transmission
and consequently the number of people still at-risk of in-
fection (and therefore the incidence of clinical infections)
(Fig. 4).
Though programmatic evidence suggests that effective
transmission of LF might cease soon after the initiation
of MDA, entomologic studies suggest that the decline in
vector infection is more gradual [18]. We therefore ap-
proximated the reductions in the number at-risk for
each country using a previously developed model which
defines reductions in risk of infection among cohorts of
treated populations following each treatment round (Fig. 3)
[18]. As populations are treated, their risk of infection di-
minishes progressively after each MDA. The model was
parametrised based on previous studies, which estimated a
relationship describing an ‘average’ rate-of-decline of vec-
tor infection over five treatment rounds (pooling data
from available studies [19–25]). This method uses the pro-
gressive decrease in vector infection rates as an indicator
for decreased transmission, and, therefore, reduced popu-
lation at risk of LF.
The model therefore accounts for a gradual decline in
transmission, namely reductions of pre-control levels of
50, 75, 88, 94 and 95 % for the treated population follow-
ing each of the first five MDA rounds respectively [18].
For this analysis, the reductions for the fifth MDA round
onwards was set to 95 % and not the previous 100 % to ac-
count for potential residual transmission. These values
were varied in the sensitivity analysis. The reductions in
transmission are applied only to those treated and not the
at-risk population as a whole (Fig. 3) [18].
The number of clinical infections prevented in this
benefit cohort was estimated by assuming that in the
Fig. 2 Baseline model assumptions. Assumptions based on [2, 4]. The sources for the parameters are outlined in Table 3
Table 3 Baseline model parameters (based on [2, 4])
Parameter Hydrocele average estimate Lymphedema average estimate Source
Acute Disease
Percentage of clinical patients who experience ADL episodes per year 70 % 95 % [8, 10–17]
Frequency of ADL episodes for clinical patients (in absence of MDA) 2 per year 4 per year [8, 10–17]
Average duration of an ADL episode 4 days 4 days [8, 10–17]
Reduction in the frequency of ADL episodes by MDA 50 % 50 % [33, 36, 37]
Chronic Disease
Percentage in different clinical disease states 62.5 % 37.5 % [7]
Percentage of chronic disease alleviated by MDA 10 % 15 % [20, 30–35]
Due to the lack of region-specific data, a standard rate or proportion was utilized for each GPELF country. ADL acute adenolymphangitis, MDA mass
drug administration
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Fig. 3 Schematic representation of the benefit cohorts and the assumed impact of treatment. *The number of uniquely treated individuals in any
one country was assumed to be the maximum number of individuals treated in any single MDA for each country
Table 4 Percentage of clinical patients seeking treatment
Parameter Hydrocele average estimate Lymphedema average estimate Source
Percentage of patients with ADL seeking treatment per episode 55 % (India: 70 %) 55 % (India: 75 %) [8, 11, 14, 44, 46]
Percentage of chronic disease patients seeking treatment 20 % (India: 50 %) 30 % (India: 55 %) [9, 44, 45]
Based on [4], though updated where appropriate. ADL acute adenolymphangitis
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absence of MDA, approximately 10 % of the projected
population no longer at-risk would have become in-
fected [2, 4], and 33 % of those would have developed
clinical disease (Fig. 3). This is a modification of the pre-
vious analysis [4], which modelled newborns who are
protected from infection over their lifetimes and other
individuals protected from acquiring infection separately.
The updated model [18] was used as it more accurately
quantifies the impact of MDA on transmission and the
reduction of the at-risk population as a whole.
The 17 countries that have passed the Transmission
Assessment Survey (TAS) for all of their endemic dis-
tricts/implementation units and stopped MDA were as-
sumed to have an at-risk population of zero from that
point onwards (before passing the TAS they had the trans-
mission reduction rates described previously (see Fig. 3)).
Benefit Cohort 2: individuals with existing subclinical
morbidity protected from progression to clinical disease
Based on previous studies it was assumed that approxi-
mately 66 % of individuals infected with LF have subclin-
ical morbidity [1] and about 50 % of these would
progress to overt clinical disease in their lifetimes [2, 4].
As in the previous analysis [2, 4], it was conservatively
assumed that MDA halts disease progression in 50 % of
those who would have progressed from subclinical to
clinical disease [26].
Though the number of individuals treated in each
MDA round for each country is known [5], it is not pos-
sible to estimate how many different individuals received
treatment across multiple MDA rounds. Consequently,
a conservative approach was taken and the number of
uniquely treated individuals in any one country was
assumed to be equal to the maximum number of indi-
viduals treated in any single MDA round [5].
Benefit Cohort 3: individuals with existing clinical morbidity
for whom clinical morbidity was alleviated
There remains considerable uncertainty regarding the
extent to which MDA improves the state of morbidity in
those already suffering from hydrocele or lymphedema.
However, several studies have provided preliminary evi-
dence that repeated rounds of MDA may alleviate some
LF clinical morbidity [20, 27–31]. As in the previous
analysis [4], a conservative estimate of 10 % of the mor-
bidity of hydrocele cases and 15 % of the morbidity of
lymphedema cases being alleviated by MDA was as-
sumed. However, due to the uncertainties surrounding
these values, they were varied in the sensitivity analysis
(ranging from 0 % alleviation up to 69–90 % based on
the lower and upper boundaries cited by the literature
[20, 30–35]).
Treatment is also known to reduce the frequency of ADL
episodes experienced by chronic patients [33, 36, 37].
Due to the uncertainty surrounding this parameter, we
assumed a conservative estimate of a 50 % reduction in
the frequency of ADL episodes in chronic patients and
varied this between 15 and 88 % in the sensitivity ana-
lysis [33, 36, 37] (Fig. 3).
Calculating the total health and economic benefits of the
GPELF
In this paper we investigated the total health and eco-
nomic impact of the GPELF for the three benefit cohorts
defined in the previous section for the years 2000–2014. In
the absence of transmission, protection from LF infection
Fig. 4 The estimated decline in the number of people at-risk of LF infection over time. The reductions were projected using the model presented
in [18] and Fig. 3. Since a few countries are still doing mapping/have not started, the numbers at-risk remain incompletely defined. If a country
has passed the Transmission Assessment Survey (TAS) in all of its implementation units it was assumed to have an at-risk population of zero (from
that point forward)
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and disease progression is lifelong, thus it is necessary to
aggregate the total health and economic benefit gained over
the remaining lifetime of each benefit cohort population
(Fig. 5). Life expectancy estimates were taken from existing
tables [38]. The calculations were performed for each
country individually to account for country-specific differ-
ences (such as life expectancy, mortality rates, medical ex-
penses, wages etc.). All calculated economic benefits were
discounted at 3 % to the base year of 2014.
The perspective of the analysis was that of the society
as a whole – including the costs incurred by the patients
(both direct and indirect costs), and national health
systems.
Duration of health and economic benefits
The duration of the health and economic benefits was
dependent on A) the age of onset of clinical disease (as-
sumed to be 20 years old [2] in each country), B) the
average life expectancy (differing by country), and C) the
mean age at which an individual received MDA treat-
ment (differing by cohort). For the latter the following
assumptions were made (based on [4]):
 Individuals protected from acquiring infection
(Benefit Cohort 1): The model assumes that the
average age at treatment (and thus protection) for
this cohort is 20 years.
 Individuals with subclinical morbidity at the time of
MDA (Benefit Cohort 2): Though subclinical
infection is common in early childhood, the model
assumes that the average age at treatment (and thus
protection) for subclinical patients is also 20 years.
 Individuals with clinical disease at the time of MDA
(Benefit Cohort 3): The model assumes these
individuals to be 30 years old on average when they
receive MDA. This estimate implies that clinical
disease patients have been living with their
condition for an average of 10 years, since onset of
clinical disease is assumed to be 20 years of age.
In the model, these average ages (20, 20 and 30 years)
were used to encompass the entire age range of individ-
uals within each benefit cohort population at the time of
treatment – accounting for the fact that, in reality, some
individuals receiving treatment will be younger or older
than the average age (Fig. 5) [4].
Population size
This study projects the total health and economic im-
pact of the first 15 years of the GPELF by aggregating
the benefits over the lifetime of the 2000–2014 benefit
cohorts. No projections are made for the expansion of
MDA programmes after 2014 or their resulting benefits.
The size of the benefit cohort populations were set to
decrease dictated by the country-specific mortality rates
[39]. Because the model population size decreases over
time, the economic-benefit denominator was analysed in
Fig. 5 Duration of the health and economic benefits for the different benefit cohorts. The base year of the analysis was 2014. Health and
economic benefits are calculated only for the benefit cohort populations receiving MDA between 2000 and 2014 (red bar); however, the benefits
are gained until the end of their lifetime (green bar). For modelling purposes, single average ages were used to encompass the entire age range
of individuals in each population benefit cohort accounting for the fact that, in reality, some individuals receiving treatment will be younger or older
than the average age. The size of each benefit cohort decreases each year based on country and age-specific mortality rate. Figure based on [4]
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person-years (the sum of each year lived by each individ-
ual in each benefit cohort population).
DALYs averted
The number of disability-adjusted life years (DALYs)
averted due to the GPELF (2000–2014) was estimated by
applying the 2010 Global Burden of Disease (GBD) dis-
ability weight of 0.11 (0.073–0.157) [40] to the number
of clinical (symptomatic) LF person years averted (sum
of each year lived by each individual in the benefit co-
hort population (Fig. 5)). No distinction in the disability
weight was made between hydrocele and lymphedema.
Based on the methodology employed by the 2010 GBD
study we did not apply a discount rate or age weighting
to the DALY estimates [41].
Economic costs prevented
All of the economic benefits from MDA were assumed
to arise from individuals within the benefit cohorts (i.e.
individuals who would have had clinical disease without
the GPELF). The economic costs prevented are com-
prised of both:
 Direct costs: representing the costs associated with
medical resource utilization, which include the cost
borne by the patients (i.e. for the medicines and
transport etc.) and the health system (i.e. for health
care personnel and capital resources etc.) [42].
 Indirect costs: defined as the expenses incurred
from the cessation or reduction of work as a result
of the morbidity and mortality associated with a
given disease [42].
Direct costs
Patient medical expenses Medical expenses are incurred
by patients with clinical morbidity seeking treatment
(Table 4). Patients were assumed either to go to a public
or private health facility or to perform self-treatment/use
traditional healers (Additional file 2: Table S1). Chronic
disease sufferers who seek treatment following bouts of
severe pain and swelling were assumed to receive anti-
inflammatory medicines (ibuprofen (400 mg), and para-
cetamol (500 mg)). Patients seeking treatment for ADL
were assumed to receive the same anti-inflammatory
medicines and antibiotics (amoxicillin (500 mg)) [43].
We conservatively assumed that the standard treatment
course was 8 days.
Both the proportion of clinical patients who seek treat-
ment (Table 4) and the treatment source (Additional file
2: Table S1) were dependent on the morbidity type. In
India, a higher proportion was assumed to seek treat-
ment and to go to health facilities (Table 4). Due to lack
of data, a lower global estimate was used for the other
GPELF counties (Table 4). It was also assumed that the
chronic hydrocele and lymphedema patients seeking
treatment would do so an average two and three times
per year respectively.
As in the previous analysis [4] it was assumed that for
individuals seeking treatment at health facilities (both
public and private), 50 % of their total medical expenses
was for the medicines, 30 % for consultation fees and
20 % for transport, food, and accommodation [11, 44–46].
Median international reference prices for a course of
amoxicillin (500 mg), ibuprofen (400 mg), and paraceta-
mol (500 mg) were collected from the Management Sci-
ences for Health International drug price indicator guide
[47]. These were adjusted to obtain country-specific cost
estimates for both public and private treatment using the
Median Price Ratios from the relevant Health Action
International database [48]. For countries not listed, the
lowest value within the same region was used as a proxy.
These medicine costs (which are 50 % of the total cost)
were doubled to arrive at the estimated total medical ex-
penses. For self-treating individuals, only the private medi-
cine costs for ibuprofen and paracetamol were attributed
to the total medical expenses. A summary of the medical
expenses for each region is shown in Additional file 2:
Table S2.
Health system costs Reductions in the number of clin-
ical cases will also reduce the amount of medical care that
needs to be provided for LF, and consequently financial
costs to the health systems of endemic countries. To esti-
mate these patient-service savings, country-specific costs
for a consultation at a rural primary health centre were
gathered from the WHO CHOICE database [49]. These
costs were then multiplied by the number of clinical LF
cases averted, the percentage that seek treatment and go
to a public health facility (Table 4 and Additional file 2:
Table S1), and the average number of treatment visits per
year (Table 3). Note that the WHO CHOICE database was
updated in 2011, hence the health system costs are differ-
ent from [4]. A summary of the average health system
costs per visit for each region is shown in Additional file
2: Table S2.
Due to the absence of data regarding the cost and ac-
tual number of hydrocele surgeries performed in en-
demic countries, it was not possible to incorporate their
costs into the analysis [43]. However, the proportion of
total direct costs related to hydrocele surgeries would
likely be small due to the still inadequate, relatively low
frequency of hydrocelectomies.
Indirect costs
Lost wages Clinical LF is debilitating, and patients are
unable to work the same number of hours as equivalent
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workers not experiencing clinical symptoms (although
chronic disease is less debilitating than acute (ADL) epi-
sodes). Reduced work hours and economic activity due
to LF morbidity results in income loss for clinically in-
fected individuals (an indirect cost).
Our assumptions regarding the reduction in productivity
due to LF morbidity (Table 5) were based on a number
of studies reporting the average number of hours worked
by those with clinical disease compared to LF disease
free controls (therefore accounting for employment rates
in the local study setting). The difference between cases
and controls is the percentage of working hours lost due
to LF morbidity. It should be noted that these cost-of-
illness studies must be interpreted with a degree of cau-
tion, as they are often highly sensitive to methodological
assumptions; hence we employed conservative values
(Table 5) and varied them over a wide range in the sensi-
tivity analysis. We included both the productivity lost
due to chronic disease and ADL episodes within our cal-
culations of the indirect costs (Table 5).
As in [4], the indirect cost estimates were calculated
using the human capital approach (i.e. based on the income
foregone as a result of illness (any hour not worked is
counted as an hour lost)) [50–52]. It should be acknowl-
edged that approximating the income for individuals with
LF is difficult; for example many of those infected are sub-
sistence farmers who do not participate in the formal
labour market [4]. For this reason, a combination of four
wage sources was used to estimate the country-specific fair
market value of time for an agricultural worker with LF in-
fection (as in [4]): A) The International Labour Organiza-
tion’s LABORSTA database (which lists country-specific
average wages for agricultural field workers) [53]; B)
The World Bank’s World Development Indicators (which
lists a country-specific average value added per agricultural
worker) [54]; C) The International Labour Organization’s
Minimum Wages Database [55] and D) United States
Department of State Country Reports on Human Rights
Practices (which both list country-specific minimum
wages) [56]. To ensure a conservative estimate, the lowest
wage value was used for countries listed by more than one
of the sources. For countries not listed by any of the four
sources, the lowest value within the same region was used
as a proxy. It was assumed that all individuals at-risk of or
infected with LF would have been potentially economically
active otherwise, and would work 300 days per year (six
days a week, 50 weeks a year), 8 hours a day. A summary
of the wages for each region and source is shown in
Table 6.
Cost standardization
To standardize the treatment prices and wages over dif-
ferent time periods, all estimates were adjusted for infla-
tion using the gross domestic product price deflator and
are expressed in US$ 2014 prices [57]. Estimates were
then converted from local currencies to US dollars using
the average exchange rates for 2014 [58].
Discounting
The base year for calculating economic benefits was set
to 2014. The economic benefits were discounted at 3 %
per year from this time point in accordance to guidelines
set by WHO-CHOICE [59]. The discount rate was varied
(0–6 %) within the sensitivity analysis [59]. No discount
rate was applied for the years prior to the base year
(2014). The DALYs averted/health benefits were not dis-
counted in this analysis [41].
Sensitivity analysis
Sensitivity analysis was performed in the following areas;
A) Disease progression and incidence rates, B) Patient
medical expenses and treatment seeking behaviour, C)
Table 5 Economic model parameters





Acute Average patient medical expenses per ADL episode Country-specific (US$1.18a) Country-specific (US$1.18a) [8, 11, 44–48]




Country-specific (US$1.05ac) [8, 11, 44–48]
Acute Percentage of work hours lost per day during an
ADL episode
75 %b 75 %b [12, 14, 16, 87]




Average wage per day (minimum of sources
(Table 6))
Country-specific (US$1.50a) Country-specific (US$1.50a) [53–56]
Chronic Work days per year 300b,d 300b,d
Based on [4], though updated where appropriate
aWeighted average over all GPELF countries (based on the benefit cohort population size in each country) (Additional file 2: Table S2 and Table 6)
bGlobal estimate indicates a standard rate or proportion was utilized for each GPELF country. This is primarily due to a lack of supporting country-specific data
cChronic hydrocele and lymphedema patients are assumed to seek treatment on average two and three times a year respectively
dAssume an average 6 day work week, 50 weeks of the year
Costs are expressed in US$ 2014 prices
ADL acute adenolymphangitis
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Lost productivity and wages, D) The discount rate and
E) Impact of treatment. The parameters and ranges in-
vestigated are shown in Table 7.
Ethical approval
This study does not require ethical approval.
Results
Between 2000 and 2014, the GPELF has delivered 5.6
billion treatments to over 763 million people at least
once, in 61 of the 73 identified endemic countries.
Using the model presented in Fig. 3 and the corre-
sponding treatment data, we projected that the total
benefit cohort of the GPELF (2000–2014) would consist
of 46 million individuals (Table 8) (i.e. these individuals
would have had clinical disease without the GPELF in-
terventions). Of these, 21 million (45 %) were in Benefit
Cohort 1 (would have acquired LF and subsequently
progressed to clinical disease but were protected from
infection due to reductions in transmission by MDA).
The remaining 25 million were individuals who were
already infected at the time of MDA treatment but bene-
fited from halted disease progression (Benefit Cohort 2:
12.5 million (27 %)), or alleviated clinical disease (Benefit
Cohort 3: 12.8 million (28 %)) (Table 8).
Health benefits
Administering MDA to such a large population has pro-
duced substantial health benefits over the first 15 years
of the GPELF. We estimate that the programme would
prevent 1,592 million years lived with chronic disease
(36 million chronic cases) and 4,689 million ADL epi-
sodes over the lifetimes of the benefit cohorts (Table 9).
This translates into approximately 175 (116–250) million
DALYs averted – range depending on the 95 % uncer-
tainty range of the disability weight (Table 9).
The total health impact was smallest for the Alleviated
clinical disease cohort (Benefit Cohort 3) despite its
comparable population size (Table 8). This is due to the
fact that the majority of this cohort were only experien-
cing reductions in the frequency of ADL episodes and
not fully alleviated chronic disease (Table 9) (due to the
assumed effects of treatment on morbidity (Table 3 and
Fig. 3)). Furthermore, as members of this cohort were
assumed to be older at the time of MDA, they have
fewer years of economic benefit (and consequently a
lower number of person-years in the benefit cohort
(Fig. 5 and Table 8)).
Economic benefits
We estimated that on average, each individual in the
benefit cohort will potentially avoid losing US$2 095
over his/her lifetime (US$50 per year) (Tables 10 and
11). This is equivalent to the income earned by working
33.3 days per year (Table 10). Though these sums and
averages vary between different regions (Table 10 and
Additional file 2: Table S4), much of the variation can be
attributed to higher wages in non-AFRO/SEARO coun-
tries (Table 6) (where only 4 % of the treatments during
this 15-year period have been given (Fig. 1)). It is im-
portant to note that each year after 2014, the economic
benefit is discounted by 3 % per year.
In total, we estimated that due to the notable health
impact of the GPELF, individuals in the benefit cohort
would avoid losing US$96.9 billion in costs over their
lifetimes. This total amount results from summing the
prevented patient medical expenses (US$2.9 billion) and
potential income loss (US$94 billion) prevented for these
individuals (Table 11). Reductions in the number of clin-
ical LF cases will also reduce the patient-service costs for
the public health system. We estimated that approximately
US$3.5 billion in health system costs will be saved over the
lifetime of the benefit cohort populations. Consequently,















AMRO $6.90 $27.36 $5.27 $5.17 $27.36 $5.11
AFRO $1.92 $8.18 $2.06 $2.16 $9.05 $1.01
EMRO $4.84 $18.26 $3.19 $5.00 $18.26 $3.00
WPRO $5.36 $9.06 $6.81 $6.74 $10.70 $4.98
SEARO $1.80 $3.47 $1.77 $3.75 $4.04 $1.47
Average $2.02 $5.10 $2.10 $3.42 $5.84 $1.50
AMRO Region of the Americas, AFRO African Region, EMRO Eastern Mediterranean Region, WPRO Western Pacific Region, SEARO South-East Asia Region,
ILO International labour organization
Results in this paper use the “Overall average – minimum of sources” estimates
Values shown are weighted averages (based on the benefit cohort population size in each country)
aThe overall maximum and minimum averages were estimated from all sources for each country individually, and then averaged by region (which is why the
values are smaller than the regional database averages)
Costs are expressed in US$ 2014 prices
For countries not listed in the database, the lowest value within the same region was used as a proxy
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Disease Progression & Incidence Rates
Percentage of clinical patients who experience ADL episodes per year 70 % (45–90 %) 95 % (90–95 %) [8, 10–17]
Frequency of ADL episodes for clinical patients (in absence of MDA) 2 (0–7) per year 4 (0–7) per year [8, 10–17]
Average duration of an ADL episode 4 (1–9) days 4 (1–9) days [8, 10–17]
Disability weight for symptomatic LF infection 0.11 (0.073–0.157) 0.11 (0.073–0.157) [40]
Mean age of the benefit cohorts (years) Cohort 1: 20 (30) Cohort 1: 20 (30)
Cohort 2: 20 (30) Cohort 2: 20 (30)
Cohort 3: 30 (40) Cohort 3: 30 (40)
Patient Medical Expenses and Treatment Seeking Behavior
Percentage of patients with ADL seeking treatment per episode 55 % (55–70 %) 55 % (55–70 %) [8, 11, 14, 44, 46]
India 70 % (70–98 %) (India 75 % (75–98 %))
Percentage of chronic disease patients seeking treatment 20 % (20–50 %) 30 % (30–55 %) [9, 44, 45]
India: 50 % (41–80 %) India 55 % (48–100 %)
Average patient medical expenses per ADL episode +−20 % of baseline value +−20 % of baseline value [8, 11, 44–48]
Average patient medical expenses for chronic disease per year +−20 % of baseline value +−20 % of baseline value [8, 11, 44–48]
Lost Productivity & Wages
Work days per year 300 (261–365) days 300 (261–365) days
Percentage of work hours lost per day during an ADL episode 75 % (50–93 %) 75 % (50–93 %) [12, 14, 16, 87]
Percentage of work hours lost due to chronic disease 15 % (9–24 %) 19 % (11–31 %) [12, 43, 45, 46]
Discounting
Discount rate 3 % (0–6 %) 3 % (0–6 %) [59]
Impact of Treatment
The reduction in transmission experienced by the treated population Year 1: 50 % (35 %) Year 1: 50 % (35 %) [18]
Year 2: 75 % (53 %) Year 2: 75 % (53 %)
Year 3: 88 % (62 %) Year 3: 88 % (62 %)
Year 4: 94 % (66 %) Year 4: 94 % (66 %)
Year 5 95 % (67 %) Year 5 95 % (67 %)
Reduction in the frequency of ADL episodes by MDA 50 % (15–88 %) 50 % (15–88 %) [33, 36, 37].
Percentage of chronic disease alleviated by MDA 10 % (0–90 %) 15 % (0–69 %) [20, 30–35]
Based on [4], though updated where appropriate. ADL acute adenolymphangitis, MDA mass drug administration
Table 8 Summary of the benefit cohorts
Benefit cohort Population size
(millions)
Average age at MDA
treatment




1. Protected from acquiring infection 21 20 45.6 938
2. Subclinical morbidity prevented from progressing 12.5 20 45.6 551
3. Alleviated clinical disease 12.8 30 35.6 450c
Total 46 - - 1,939
aBased on a global weighted average life expectancy of 64.6 years (weighted based on the benefit cohort population size in each endemic country)
bThe sum of the number of years lived by each individual in the benefit cohort population. (Equal to the benefit cohort population multiplied by the average
years of health and economic benefit (after adjusting for mortality))
cIncludes both those with alleviated chronic disease and these with reduced frequency of ADL episodes (Fig. 3)
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the total economic impact for both the individuals in the
benefit cohort and the health system was estimated to be
potentially US$100.5 billion (Table 11).
Economic benefits by cost type
Approximately 93.6 % of the projected total economic
benefit can be attributed to the prevention of reduced
productivity and subsequent income loss – an indirect
cost (Fig. 6 and Table 11). The remaining benefit was re-
lated to prevented patient medical expenses (2.9 %) and
health system costs prevented (3.5 %) – both direct costs.
The relatively low proportion for prevented patient med-
ical expenses was attributable to the low frequency of
treatment seeking behaviour and relatively inexpensive
medicine packages relative to the day-to-day accumulation
of lost income from reduced economic activity.
Economic benefits by morbidity type
The total economic benefits accrued by populations pro-
tected from hydrocele were approximately equal to those
from lymphedema (Fig. 7). This result occurred because
the greater average disability of lymphedema patients
(Table 3) offsets the estimated higher proportion of clin-
ical disease patients with hydrocele (62.5 % vs 37.5 %).
Prevented chronic disease accounted for about 81 % of
the total economic benefits (Fig. 7). This is to be expected,
as though acute episodes are more debilitating, they have
a short duration (8–16 days per year) – whereas the
chronic condition is a life-long disability (Table 3).
Sensitivity analysis
To determine how sensitive the results were to variation
in the input parameters and assumptions, the model
projections were subjected to univariate sensitivity ana-
lysis (see Table 7 for a full description).
The projected impact on health was found to be very
robust, with the number of DALYs averted only being
reduced by 17 % when assuming more conservative re-
ductions in transmission, and 18 % when increasing the
mean age of the benefit cohorts by 10 years (Additional
file 2: Table S5). When assuming that MDA has no im-
pact regarding alleviating established chronic disease,
the number of DALYs averted only decreased by 7 %
(and increased by 37 % when using the upper range of
reported values for this parameter) (Additional file 2:
Table S5). The number of DALYs averted was sensitive
to the assumed disability weight. However, even when
using the lower bound (0.073) for the disability weight
[40], we still projected that 116 million DALYs would
be averted.
The sensitivity of the economic benefit of the GPELF
to the different parameters is shown in the tornado dia-
gram in Fig. 8 (which illustrates the percentage change
in the total economic benefit when changing each of the
model parameters in Table 7). The results were most
sensitive to the assumed percentage of work hours lost
due to chronic disease and when using the lower bound
the total economic benefit decreased by 31 % (Fig. 8).
The Figure also illustrates that if a lower discount rate
was assumed that the economic benefit would be even
Table 9 Projected health impact of the GPELF (2000–2014) over lifetime of the benefit cohorts
Benefit cohort Number of chronic cases
averted (millions)
Years of chronic disease
averted (millions)




1. Protected from acquiring infection 21 938 2,157 103 (68–147)
2. Subclinical morbidity prevented from progressing 12 551 1,267 62 (41–88)
3. Alleviated clinical disease 3 104 1,264 11 (8–16)
Total 36 1,592 4,689 175 (116–250)
aRange based on the 95 % uncertainty interval of the disability weight (Table 7)
See Additional file 2: Table S3 for the results stratified by WHO region. ADL acute adenolymphangitis
Table 10 Costs prevented per individual of the benefit cohort population
WHO
region
Annual medical expenses averted per
person within the benefit cohorta
Annual wage loss prevented per
person within the benefit cohorta
Annual economic benefit per
person within the benefit cohorta
Equivalent number of
days income per yearab
AMRO $1.75 $158.49 $160.24 31
AFRO $0.77 $30.15 $30.92 31
EMRO $0.62 $102.54 $103.17 34
WPRO $1.32 $160.07 $161.39 32
SEARO $1.91 $50.37 $52.27 36
Average $1.52 $48.48 $50.00 33.3
AMRO Region of the Americas, AFRO African Region, EMRO Eastern Mediterranean Region, WPRO Western Pacific Region, SEARO South-East Asia Region. Costs are
expressed in US$ 2014 prices
aDoes not include reduction in costs to the health system (Additional file 2: Table S4)
bAnnual economic benefit per person within the benefit cohort divided by the average wage estimate for that region (Table 6)
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larger (and vice versa). The sensitivity analysis stratified
by cost type is shown in Additional file 2: Table S6.
Discussion
These results further highlight that LF is responsible for
not only a severe physical burden but also a considerable
economic burden (from both medical expenses and loss
of income-generating activity). The notable and sus-
tained losses in labour productivity for clinical LF pa-
tients make it even harder for those living in endemic
areas to escape from poverty without the aid of MDA
interventions.
We projected that due to the first 15 years of the
GPELF 36 million chronic cases would be averted (Table 9).
Over the lifetime of the benefit cohort, this corresponds to
175 (116–250) million DALYs being averted (Table 9).
We estimated that, as a result of the first 15 years of
the GPELF, 46 million individuals will gain economic
benefits due to prevented clinical disease (Table 8) and
that members of this benefit cohort would avoid losing
US$96.9 billion in costs (an average of US$2 095 per
person) over their lifetime due to the GPELF (Table 11).
For individuals within the benefit cohort this is equivalent
to the income earned from working 33.3 days (or 11 % of
their average annual income (Table 10)). In addition to the
economic benefits to individuals, we projected US$3.5 bil-
lion in health system costs will be saved in endemic areas
(Table 11). Such savings are critical for health systems in
resource poor settings. Furthermore, it is important to
acknowledge that the analysis did not account for the
decreasing need for hydrocele surgeries due to the
MDA, and is therefore underestimating the economic
benefits to health systems. The total economic impact
for both the individuals and the health systems was es-
timated to be US$100.5 billion.
Comparison to past estimates
A previous analysis by Chu et al. [4] estimated that fol-
lowing the first 8 years of the GPELF (2000–2007),
US$21.8 billion of economic benefits will be gained in
MDA-treated areas, in addition to US$2.2 billion in
health systems savings. The difference in values between
the studies are primarily due to the following reasons.
1. The analysis presented in this paper estimated the
impact of the GPELF between 2000 and 2014. Since
2007, the programme has expanded to an additional
13 countries and delivered over 3.68 billion more
treatments (Table 2 and Fig. 1) – therefore the
economic impact has increased.
2. The number of individuals protected from acquiring
infection (Benefit Cohort 1) was estimated using a
model [18] defining reductions in the risk of
infection among cohorts of treated populations
(Fig. 3). This is a modification of the previous
analysis [4] – as the model [18] was not developed
Table 11 Total costs prevented for individuals and the health systems over lifetime of the benefit cohorts




individuals prevented - lost
wages (millions)









1. Protected from acquiring infection $1,376 $52,513 $1,813 $55.70 $2,569
2. Subclinical morbidity prevented
from progressing
$818 $31,273 $1,063 $33.2 $2,572
3. Alleviated clinical disease $744 $10,210 $664 $11.6 $855
Total $2,938 $93,996 $3,540 $100.5 $2,095b
aDoes not include the economic benefit to the health system
bWeighted average
See Additional file 2: Table S4 for the results stratified by WHO region. Costs are expressed in US$ 2014 prices
Fig. 6 Total economic benefit disaggregated cost type
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at that time. Consequently, the size of the benefit
cohort is substantially larger in this more recent
analysis.
3. The assumed wages were higher than the values
used in [4] (due to inflation and the fact that the
databases used to obtain wage estimates are now
more complete).
4. WHO Choice updated its cost database in 2011 and
consequently, the assumed health care costs (per
visit) are different from those in Chu et al. [4].
Other studies corroborate the finding that the largest
economic burden of LF results from indirect costs (see
[43, 60]). For example, it was estimated that in India,
8 % of the potential male labour input was being lost
due to hydrocele and lymphedema [45]. This was
subsequently valued at US$704 million per year [50]. In
Ghana a similar values was reported, with more than
7 % of potential labour lost [9].
That we know of, there are very few other analyses of
health and economic benefits of global health programs
as a whole. This makes it difficult to compare these esti-
mates to those of other global disease control programmes.
However, it should be noted that large health gains can also
be expected for programmes targeting other NTDs as we
move towards the goals set be the London Declaration and
WHO 2020 NTD roadmap [61, 62].
Within [61] it was estimated that if the London Dec-
laration goals were met between 2010 and 2030, 46.4
new clinical LF cases would be averted. This appears
comparable with our estimate of 33 million new cases
being averted over the lifetime of benefit cohorts 1 and
Fig. 7 Total Economic benefits by morbidity type, and clinical presentation
Fig. 8 Tornado plot illustrating the impact of the sensitivity analysis on the estimated total economic benefit of the GPELF (2000–2014). The
parameter ranges investigated are shown in Table 7. Results stratified by cost type are shown in Additional file 2: Table S6
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2 (for the treatments given between 2000 and 2014) –
though it is difficult to directly compare the estimates as
they are analysing different time horizons.
Reduced productivity and lost wages
The majority (93.6 %) of the economic benefit was pro-
jected to arise from potential income loss prevented (indir-
ect costs). A variety of methods in valuing working time
have been incorporated in economic analyses of similar
tropical diseases, including the examination of minimum
wages [63], average value added per agricultural worker
[64], and proxies from prior studies in similar settings [65].
We used a combination of four wage sources to estimate a
fair market value of time for an agricultural worker with LF
infection (to ensure a conservative estimate, the lowest
wage value was used for countries listed by more than one
of the sources). For women, economic activity includes
time spent on non-agricultural household chores (an op-
portunity cost). Our calculations used the human capital
approach (which counts any hour not worked by a patient
as an hour lost (Table 1)) [50–52].
However, approximating the value of the income loss
is difficult for a variety of reasons [4, 52]. Firstly, the ma-
jority of this population is comprised of subsistence
farmers who do not participate in the formal labour
market, making it harder to place a value on their time
[4]. Furthermore, although chronic patients may develop
coping strategies to adapt to their condition and regain a
degree of economic activity, many do so at the expense
of lower-earning jobs that require less physical activity
[9, 66] – which is difficult to quantify. In addition, many
with severe morbidity will be confined to the home and
likely have to give up income-generating activity com-
pletely [4]. It is also important to consider that many pa-
tients may be employed in occupations with higher wages
than subsistence farmers (such as. weaving, mining, fish-
ing) [4] and will therefore suffer a higher opportunity cost
than assumed in this analysis; average incomes are also
generally higher in urban areas, where up to a third of the
LF burden in India exists [50, 67]. More socioeconomic
research is necessary to yield greater accuracy in the esti-
mates of the opportunity cost of LF and indirect economic
benefits of the GPELF [4].
It should be noted that there was a substantial degree
of variation in the wage estimates between the different
databases (Table 6) and employment rates may vary
across the different countries. To be conservative we
used the lowest wage estimate for each country (Table 6).
Furthermore, our analysis calculates indirect costs based
on the equivalent hours and resulting wages lost from
economic activity. However, this ignores the fact that as
well as working less, LF patients may be less productive
while at work [4]. For example, Ramu et al. found that
though the reported time difference (hours worked)
between LF infected and uninfected weavers was 15–
20 %, the productivity gap was higher at 27 % [68]. Add-
itional research on the actual productivity burden of LF,
will be invaluable in developing more precise economic
benefit estimates in the future [4]. The sensitivity of the
results to the assumed percentage of work loss is shown
in Fig. 8 and Additional file 2: Table S6.
Additional benefits of the GPELF
Quality-of-life benefits
The primary health outcome of the analysis was the
number of DALYs averted. However, it is important to
note that the prevention of LF infection and clinical dis-
ease has led to additional quality of life benefits, which
are not captured by the DALY disability weight for LF or
the estimated lost wages. For example, the stigma associ-
ated with infection can prevent patients from playing a
full role in society, often resulting in reduced marital
prospects. This can result in adverse social and eco-
nomic repercussions not only for the patient but also
their family [69]. Furthermore, children may have to
miss school in order to care for a family member with
LF, and infected children will be more likely to miss
school or drop out completely [70]. In addition, both
those suffering from clinical disease and their caregivers
are more likely to suffer from depression which is not
currently quantified in the GBD estimates for LF –
which has been shown to underestimate LF disease bur-
den [69]. It should also be noted that DALYs fail to ac-
knowledge the implications of context on the burden of
disease, such as those for the poor –which is particularly
important for NTDs [71]. Consequently, the true value
of the GPELF will likely be higher than what is presented
in this analysis.
Economic and health impacts on other co-endemic diseases
The GPELF uses highly effective, broad-spectrum anti-
parasitic drugs (albendazole and ivermectin). Consequently,
the programme has important ancillary benefits on other
parasitic diseases (described in more detail in [2]):
 Benefit for children and for women-of-child-bearing-
age with intestinal parasites: Albendazole and
ivermectin are also used to control the soil-
transmitted helminths (STH). Consequently, the
GPELF is having a notable impact on these diseases
(Table 12). It is important to note that LF programmes
co-administrating albendazole and ivermectin will
have a much higher impact on Trichuris [72] than
STH control programmes using standalone-
treatments [73, 74]. Furthermore, these community-
wide programmes will have a higher impact on
hookworm (for which the majority of worms are
harboured by adults) [73, 75, 76].
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 Benefit for people with scabies. Ivermectin is effective
treatment for scabies and can cause the community
prevalence to fall dramatically after a few rounds of
treatment [77]. Cured individuals show improvements
in sleep patterns and overall wellbeing and decreased
incidence of skin infections and renal disease [78].
 Benefit for co-endemic onchocerciasis areas. Because
of its broad geographic range, the GPELF has brought
ivermectin treatment to millions of people living in
onchocerciasis-endemic areas not previously targeted
by onchocerciasis control programs (as these
programmes generally focused only on communities
where the prevalence of onchocerciasis exceeds 40 %)
[79]. The GPELF is therefore likely contributing
significantly to the elimination of onchocerciasis
transmission.
Limitations
Model assumptions and parameters
Though the number of individuals treated in each MDA
round for each country is known [5], it is not possible to
estimate how many unique individuals received treatment
across multiple MDA rounds. Consequently, a conserva-
tive approach was taken and the number of uniquely
treated individuals in any one country was assumed to be
the maximum number of individuals treated in any single
MDA for each country – which in most cases will be an
underestimate.
The two different drug regimens used in the GPELF were
assumed to be equally effective in their effects both on LF
disease and on the filarial infections themselves [80].
For simplicity, a single average age was used to en-
compass the entire age range of individuals within each
benefit cohort population at the time of treatment (with
the recognition that some of those receiving treatment
will be younger or older than the average age). However,
realistically the average age would vary in different coun-
tries. Though this assumption will affect the economic
benefit in any given year it is unlikely to affect the total
benefit across the benefit cohort population’s lifetime (in
the sensitivity analysis we found that if the mean ages
were increased by 10 years, it would only decrease the
total economic benefit by 10 %). It should be noted that
some of the clinical cases would be averted further into
the future then our model is projecting. Consequently,
some of the economic benefits may be under-discounted.
The limited amount of country-specific primary data
available somewhat limits the breadth of analysis pre-
sented in this paper though, much of the literature origi-
nates from India and sub-Saharan African countries
where the majority of the benefit cohort population re-
sides. Furthermore, due to a lack of regional data, many
of LF disease-specific parameters (e.g. ADL frequency
and duration, work hours lost) were attributed a global
standardized estimate. However, the sensitivity analysis
included a range of different values and the overall re-
sults appear robust.
Due to the way that the DALYs are calculated (with
the same disability weight applied to any symptomatic
infection), individuals in Benefit Cohort 3 (Fig. 3) with
reduced ADL frequency but persistent chronic disease still
had the same DALY weight applied to them. Furthermore,
Table 12 Potential impact on soil-transmitted helminths
Individuals reached Target Benefits
212 million children
-minimal estimate-
Soil-transmitted helminths (intestinal parasites:
hookworm, roundworm, whipworm)
Weight/height gain, learning ability, cognitive testing,
school attendance, fitness, activity [88–91]
Assumptions and reasoning
A) 1.1 billion treatments of albendazole given to children (aged 2–15 years old in countries treated with DEC and albendazole; 5–15 years old in
countries using ivermectin and albendazole) in 61 countries during MDAs 2000–2014 [5, 6].
B) The maximum number of children treated in any single MDA was determined for each country. The sum of these numbers indicates the
minimum total number of children treated (212 million) [5, 6].
Individuals reached Target Benefits
177 million women of childbearing age,
not pregnant (minimal estimate)
Soil-transmitted helminths (intestinal parasites:
hookworm, roundworm, whipworm)
Decreased anaemia [92], maternal mortality, infant
mortality; increased infant birth-weight [93]
Assumptions and reasoning
A) 947 million treatments of albendazole given to non-pregnant women-of-childbearing-age (aged 15–49 years old) in 61 countries during
MDAs 2000–2014 [5, 6, 38].
B) The maximum number of such women treated in any single MDA was determined for each country [5, 6]. The sum of these numbers indicates
the minimum total number of women-of-childbearing-age treated (177 million).
C) Since pregnancy is an exclusion criterion for LF treatment, the annual estimates thus derived were discounted by subtracting the estimated
percent of the female population that is pregnant at any given time.
Because individual country estimates of the prevalence and distribution of soil-transmitted helminths are generally not available, it was not possible to estimate
directly the number of soil-transmitted helminths infections. However, a sizeable proportion of the albendazole and ivermectin treatments delivered for LF will
have had a beneficial impact for children and women of childbearing age who harbour soil-transmitted helminths. The assumptions are outlined in [2]
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due to the absence of data no excess mortality of clinical
patients was assumed. These assumptions may lead to an
underestimation of the health impact of the GPELF (in
terms of the number of DALYs averted).
Calculating the reductions in the at-risk population
The model [18] used to estimate the reductions in the
at-risk population is dependent on data from WHO PCT
Databank [5] regarding the numbers of people treated
each year for LF. However, this data is self-reported by
national programs, and while in many cases it has been
found to be similar to independent coverage surveys,
there are areas where frequent over-reporting has been
identified (discussed further in [80]). Such over-reported
coverage would lead the model to overestimate the num-
ber of infections averted by the GPELF. In addition,
though data from all three mosquito genera transmitting
LF were used to generate the model parameters, the bio-
logical differences of the vectors (or vector density) are
not currently differentiated [18]. Furthermore, the model
does not take into account the possibility of re-infection
or resurgence of suppressed infections in areas that miss
rounds of treatment or in areas where the coverage has
decreased from the previous year [18]. On the other hand,
such resurgence is uncommon [1], and many features of
the model may be underestimating the effects of the
GPELF on decreasing the number of at-risk individuals.
For example, within the model, the reductions in trans-
mission are applied only to those that have been
treated. Consequently, it does not capture the indirect
or herd effects of MDA to the populations covered as a
whole [18]. The model is also based on the maximum
number treated each round (which will underestimate
the number uniquely treated). Furthermore, the model
does not ‘zero out’ an at-risk population in the country
until all of its implementation units have programmat-
ically passed the TAS [18].
Though the model has important limitations, ultimately
we are projecting that after the distribution of 5.6 billion
treatments, the global number at-risk for LF infection has
halved –which intuitively seems conservative (Fig. 4). The
model was parameterized based on data derived from a
broad range of entomological studies undertaken during
active LF MDA programs in different geographical set-
tings, providing a reliable estimate of changes in trans-
mission potential under MDA pressure. A dynamic
transmission model (such as [81–83]) would be more
ideal and accurate for quantifying the impact of MDA
on transmission (and would account for the indirect or
herd effects of the GPELF) [84]. However, in order to be
accurate this would likely require more detailed coverage
data (at least at the implementation unit level), as opposed
to the reported national coverage data available.
Conclusion
Despite the limitations of any such analysis, this study
indicates that substantial health and economic benefits
have resulted from the first 15 years of the GPELF. We
projected that due to the first 15 years of the GPELF 36
million chronic cases and 175 (116–250) million DALYs
would be averted over the lifetime of the benefit cohort.
It was estimated that due to this notable health impact,
US$100.5 billion will potentially be saved over the life-
times of those that would have had clinical disease without
the GPELF. This total amount results from summing the
patient medical expenses (US$3 billion), potential income
loss (US$94 billion), and costs to the health system
(US$3.5 billion) that were projected to be prevented
over the lifetime of the benefit cohort. The results were
subjected to sensitivity analysis and were most sensitive
to the assumed percentage of work hours lost due to
chronic disease (changing the total economic benefit
between US$69.30–150.7 billion). In addition, the GPELF
would have both further quality-of-life benefits and bene-
fits on other co-endemic diseases (such as STH) as well –
making the total health and economic value even greater
than that presented here.
It is important to note that this large health and eco-
nomic impact would be diminished if the control pro-
grammes were not continued until elimination is achieved
and the infection was allowed to resurge.
Though this analysis made a number of assumptions,
we attempted to be conservative in our approach. These
results further highlight the value and importance of con-
tinued investment in the GPELF as additional resources
will be necessary to assist the remaining countries in
implementing programs for LF elimination [4, 85].
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